Feedback PLC (LON:FDBK) has revealed that Bleepa, its flagship imaging-based medical communications platform has achieved a CE Mark for Europe.
Feedback said its directors' believe Bleepa, which allows clinicians to access medical-grade images through smartphones, tablets and desktops, is the only communication platform to address the UK market that has met Medical Devices Directive certification requirements.
In a statement, Tom Oakley, the chief executive officer of Feedback said: "We believe that Bleepa is the future for communicating about patient care and is already changing the way in which clinicians discuss cases and process patients through the hospital system. The CE mark is an important milestone in its commercialisation and sets Feedback apart from other providers."
READ Feedback's Bleepa app being evaluated as potential coronavirus tool
Oakley added: "Pennine Acute Hospitals NHS Trust and Royal Papworth Hospital NHS Foundation Trust are both demonstrating the value of using Bleepa across the hospital setting. This important regulatory milestone offers healthcare providers confidence in our product over other unregulated providers as we continue the roll-out of Bleepa in support of the NHS, both to support the fight against COVID-19 as well in day-to-day patient management."
"We believe that many NHS sites are unknowingly using uncertified tools and are therefore exposed to civil claims arising from use of those tools. Bleepa will enable Trusts to engage the digital communication revolution safely and securely within a regulated environment. Ensuring the roll out of a regulated communication platform should be a key priority for the NHS in its efforts to combat COVID-19 and beyond. Bleepa is now uniquely positioned to deliver against this need," he declared.
